| Medical and Health Sciences | Lifetime | 80 | CH 1 | 100.00 |
| Medical and Health Sciences | 2021-2025 | 299 | CH 3 | 99.94 |
| Cardiology and Cardiovascular Medicine | Lifetime | 57 | CH 1 | 99.95 |
| Medical Physiology | Lifetime | 32 | CH 1 | 99.95 |
| Surgery | Lifetime | 174 | CH 3 | 99.85 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 376 | CH 9 | 99.10 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 577 | CH 6 | 98.18 |
| Biochemistry | Lifetime | 182 | CH 4 | 97.44 |
| Immunology | Lifetime | 688 | CH 23 | 97.85 |
| Clinical Pharmacology | Lifetime | 658 | CH 10 | 97.12 |
| Internal Medicine | Lifetime | 540 | CH 11 | 80.97 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 119 | CH 3 | 99.43 |
| Surgery | 2021-2025 | 769 | CH 18 | 93.19 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 486 | CH 13 | 90.18 |
| Clinical Pharmacology | 2021-2025 | 302 | CH 6 | 87.62 |
| Medical Physiology | 2021-2025 | 785 | CH 7 | 87.11 |
| Nitric Oxide and Endothelin Effects | Lifetime | 2 | CH 1 | 99.97 |
| Renin-Angiotensin System Studies | Lifetime | 2 | CH 1 | 99.87 |
| Eicosanoids and Hypertension Pharmacology | Lifetime | 10 | CH 1 | 99.85 |
| Blood Pressure and Hypertension Studies | Lifetime | 40 | CH 1 | 99.78 |
| Takotsubo Cardiomyopathy and Associated Phenomena | Lifetime | 3 | CH 1 | 99.26 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 26 | CH 1 | 99.69 |
| Cardiac Imaging and Diagnostics | Lifetime | 100 | CH 4 | 99.81 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 58 | CH 3 | 99.64 |
| Hormonal Regulation and Hypertension | Lifetime | 76 | CH 3 | 99.48 |
| Coronary Interventions and Diagnostics | Lifetime | 97 | CH 4 | 99.68 |
| Lipoproteins and Cardiovascular Health | Lifetime | 83 | CH 1 | 99.53 |
| Heart Rate Variability and Autonomic Control | Lifetime | 151 | CH 3 | 99.22 |
| Acute Myocardial Infarction Research | Lifetime | 117 | CH 5 | 99.61 |
| Cardiovascular Issues in Pregnancy | Lifetime | 65 | CH 1 | 99.17 |
| Cardiovascular Function and Risk Factors | Lifetime | 257 | CH 2 | 99.49 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | Lifetime | 72 | CH 5 | 99.10 |
| Cardiovascular Health and Disease Prevention | Lifetime | 138 | CH 2 | 99.16 |
| Cardiac Valve Diseases and Treatments | Lifetime | 305 | CH 8 | 99.35 |
| Cardiac Ischemia and Reperfusion | Lifetime | 155 | CH 2 | 98.71 |
| Heart Failure Treatment and Management | Lifetime | 226 | CH 2 | 99.14 |
| Cardiovascular Disease and Adiposity | Lifetime | 230 | CH 1 | 98.71 |
| Cardiac and Coronary Surgery Techniques | Lifetime | 123 | CH 3 | 98.48 |
| Cardiac Structural Anomalies and Repair | Lifetime | 358 | CH 5 | 98.91 |
| Cardiovascular Syncope and Autonomic Disorders | Lifetime | 182 | CH 4 | 98.03 |
| Cerebrovascular and Carotid Artery Diseases | Lifetime | 594 | CH 19 | 98.47 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 425 | CH 8 | 98.14 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 700 | CH 18 | 98.36 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 447 | CH 3 | 98.49 |
| Cardiac Arrhythmias and Treatments | Lifetime | 763 | CH 14 | 98.15 |
| Cardiovascular Effects of Exercise | Lifetime | 431 | CH 9 | 97.54 |
| Cardiovascular, Neuropeptides, and Oxidative Stress Research | Lifetime | 120 | CH 2 | 96.93 |
| Electron Spin Resonance Studies | Lifetime | 318 | CH 11 | 97.08 |
| Cardiac pacing and defibrillation studies | Lifetime | 793 | CH 15 | 97.73 |
| Apelin-related biomedical research | Lifetime | 148 | CH 3 | 95.55 |
| Biomarkers in Disease Mechanisms | Lifetime | 129 | CH 2 | 94.92 |
| Cancer, Lipids, and Metabolism | Lifetime | 973 | CH 9 | 96.67 |
| Cardiac Health and Mental Health | Lifetime | 499 | CH 4 | 96.81 |
| Renal and Vascular Pathologies | Lifetime | 638 | CH 6 | 96.50 |
| Infective Endocarditis Diagnosis and Management | Lifetime | 927 | CH 23 | 96.79 |
| Pericarditis and Cardiac Tamponade | Lifetime | 172 | CH 1 | 95.52 |
| Angiogenesis and VEGF in Cancer | Lifetime | 831 | CH 24 | 95.59 |
| Inflammasome and immune disorders | Lifetime | 723 | CH 16 | 94.23 |
| Sodium Intake and Health | Lifetime | 328 | CH 8 | 95.16 |
| Neuroprotection in Stroke and Neurodegeneration | Lifetime | 953 | CH 9 | 92.35 |
| Health and Medical Research Impacts | Lifetime | 652 | CH 4 | 89.79 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 680 | CH 8 | 89.85 |
| Connective Tissue Growth Factor Research | Lifetime | 342 | CH 5 | 86.53 |
| Coffee research and impacts | Lifetime | 713 | CH 14 | 86.18 |
| GDF15 and Related Biomarkers | Lifetime | 631 | CH 5 | 79.51 |
| Academic Publishing and Open Access | Lifetime | 505 | CH 6 | 62.35 |
| Cardiac Imaging and Diagnostics | 2021-2025 | 165 | CH 8 | 98.65 |
| Acute Myocardial Infarction Research | 2021-2025 | 105 | CH 4 | 98.16 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 111 | CH 2 | 94.77 |
| Cardiac Health and Mental Health | 2021-2025 | 102 | CH 3 | 95.88 |
| Cardiac Valve Diseases and Treatments | 2021-2025 | 667 | CH 15 | 95.79 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 154 | CH 5 | 92.50 |
| Takotsubo Cardiomyopathy and Associated Phenomena | 2021-2025 | 42 | CH 2 | 90.84 |
| Viral Infections and Immunology Research | 2021-2025 | 781 | CH 7 | 84.08 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 897 | CH 8 | 76.36 |
